Bico Group Ab Class B · OMXSTO:BICO
Bico Group Ab Class B — Investor Day (September 2024)
100 slides from Bico Group Ab Class B's investor day presentation, Sep 17, 2024
Slide 1: BICO Capital Markets Day (CMD) 2024
BICO CAPITAL MARKETS DAY (CMD) 2024 – SEPTEMBER 17, 2024
Slide 2: Disclaimer
DISCLAIMER You must read the following before continuing. The fol- for publication, release or distribution in the United affect the extent to which a particular projection is real- lowing applies to this document and the information pro- States, the United Kingdom, Australia, Canada or Japan, ised.
Slide 3: Agenda Capital Markets Day 2024
Agenda Capital Markets Day 2024 Welcome to BICO’s Capital Markets New business areas and comment Break (15 minutes) Day on financial targets Jacob Thordenberg, CFO, BICO Jacob Thordenberg, CFO, BICO and Q&A and Anders Fogelberg, CCO, BICO Maria Forss, President and CEO, BICO Moderated by Ulrik Tratt
Slide 4: Strategy BICO 2.0
Strategy BICO 2.0
Slide 5: Vision
Vision BICO enables and automates the life science lab of the future 5
Slide 6: Mission
Mission Be the first-choice lab automation partner and provider of selected workflows to pharma and biotech 6
Slide 7: BICO in Figures
BICO in Figures Founded in 2016 65+ 12 Global Presence Companies No of Markets North Europe America 34% (33) Asia 52% (42) 13% (20) SEK 2.2bn 820+ Net Sales Rest of Employees FY 2023 the world 1% (5) 46,000+ 12,000+ Installed Share of sales per geography Publications Instruments Q2 2023 vs Q2 2024 7
Slide 8: BICO Growth Development and Acquisition Journey
BICO Growth Development and Acquisition Journey REVENUE 2017-2023 SEKm ** 2500 2,250 2000 2,121 1500 1000 1,088 500 366 45 106 13 0 2017* 2018* 2019* 2020 2021 2022 2023 8 * Split fiscal year: 2017-2018. 2018-2019, and 2019-2020 ** Ginolis divested in November 2023
Slide 9: Biosero
BIOSERO>:
Slide 10: Achievements: Four Strategic Priorities for Improvement
Achievements: Four Strategic Priorities for Improvement PRIORITIES TO PAVE WAY FOR THE UPDATED STRATEGY, BICO 2.0 1. Drive Commercial Excellence 2. Complete Strategic Review 3. Invest in People & Culture 4. Continue Operational Excellence Initiatives 10
Slide 11: 1. Driving Commercial Excellence
1. Driving Commercial Excellence Sales Skills Team for sales synergies Communications Skills Team to coordinate efforts across the Group Joint congress attendance 11
Slide 12: 2. Complete Strategic Review
2. Complete Strategic Review Full review of all R&D projects Product portfolio review Profound strategy work involving all operating companies 12
Slide 13: 3. Invest in People & Culture
3. Invest in People & Culture Global HR organization implemented HR strategy in place New corporate values launched Trust Focus Collaboration Grit 13
Slide 14: 4. Continue Operational Excellence Initiatives
4. Continue Operational Excellence Initiatives Targeted cost reduction programs Inventory reduction Supplier management Facility and Logistics optimization Project Management Office (PMO) 14
Slide 15: Executive Management
Executive Management Maria Forss Jacob Thordenberg Marius Balger President & CEO CFO COO Anders Fogelberg Catharina Nordlund Andreas Joersjö CCO CHRO General Counsel (start mid-October) 15
Slide 16: On My Route to BICO
On My Route to BICO +25 years Working in the Business development Commercialization Scaling up and experience from the whole M&A and integration of R&D projects professionalizing life science industry value chain of companies and companies in the corporate strategy same phase as Pharma AZ From procu
Slide 17: An Acquisition Journey With Bioprinting as the Core
An Acquisition Journey With Bioprinting as the Core CELLINK founded in 2016. Portfolio companies acquired between 2018-2022 Single Cell Printing Organoid/Spheroid Printing Multi-Cell Printing Tissue Printing 17
Slide 18: Later Acquisitions Serving Broader Needs
Later Acquisitions Serving Broader Needs Complementary Technologies Single Cell Printing Organoid/Spheroid Printing Multi-Cell Printing Tissue Printing – Laboratory Automation – Liquid Handling – Microscopy and Cell Analysis 18
Slide 19: Our Extensive BICO Product Portfolio
Our Extensive BICO Product Portfolio Lab automation Automating the Automated Dispensing Solutions for Hybrid 3D bioprinting Production of High-precision software and entire cell line liquid handling automation for mixing and automated products for 3D 3D printers and robotics development solutions fo
Slide 20: Strong Customer Base and Relationships in Top Pharma
Strong Customer Base and Relationships in Top Pharma* Biotech Cellino DeepCure Scribe Therapeutics Cosmetics Metagenomi Diagnostics Estée Lauder Pharma & Arpeggio Invitae Charles River Biopharma Laboratories Novo Nordisk AstraZeneca Eli Lilly EMD Sereno Astellas Merck KGaA Pfizer BMS Roche J&J Acade
Slide 21: BICO Operates in the Field of Biotechnology in Life Sciences
BICO Operates in the Field of Biotechnology in Life Sciences Life sciences Biotechnology Field of play 21
Slide 22: BICO Operates in the Field of Biotechnology
BICO Operates in the Field of Biotechnology Scientific branch Life sciences Life sciences Physical sciences Biotechnology Scientific fields Biotechnology Pharma- Biology Combination of Healthcare Genetics … living organisms cology and technology Field of play 22
Slide 23: BICO Focusing in the Preclinical Domains
BICO Focusing in the Preclinical Domains BICO focuses on the first three life science value chain steps Life sciences Value chain Drug & Basic research & (Bio)- 1 2 diagnostic 3 4 Clinical use discovery production development Biotechnology Academia & Key industry actors Research Pharma / Biotech CRO
Slide 24: BICO Offers Solutions in Molecular Biology, Drug Discovery and Synthetic Biology
BICO Offers Solutions Predominantly in Molecular Biology, Drug Discovery and Synthetic Biology BICO focuses on the first three life science value chain steps Life sciences Value chain Drug & Basic research & (Bio)- 1 2 diagnostic 3 4 Clinical use discovery production development Biotechnology BICO’s
Slide 25: BICO's Portfolio of Solutions Serves Selected Workflows
BICO’s Portfolio of Solutions Serves Selected Workflows Synthetic Fields Molecular biology Drug discovery biology Applications / Basic Transla- tional Diagnostic Diagnostic Target Hit Generation & Lead Optimi- Animal Clinical Biologics, Proteins, and Small Molecule Manu- Activities Research Research
Slide 26: BICO's Portfolio of Solutions Serves Selected Workflows
BICO’s Portfolio of Solutions Serves Selected Workflows Synthetic Fields Molecular biology Drug discovery biology Applications / Basic Transla- tional Diagnostic Diagnostic Target Hit Generation & Lead Optimi- Animal Clinical Biologics, Proteins, and Small Molecule Manu- Activities Research Research
Slide 27: BICO's Portfolio of Solutions Serves Selected Workflows
BICO’s Portfolio of Solutions Serves Selected Workflows Synthetic Fields Molecular biology Drug discovery biology Applications / Basic Transla- tional Diagnostic Diagnostic Target Hit Generation & Lead Optimi- Animal Clinical Biologics, Proteins, and Small Molecule Manu- Activities Research Research
Slide 28: BICO's Portfolio of Solutions Serves Selected Workflows
BICO’s Portfolio of Solutions Serves Selected Workflows Synthetic Fields Molecular biology Drug discovery biology Applications / Basic Transla- tional Diagnostic Diagnostic Target Hit Generation & Lead Optimi- Animal Clinical Biologics, Proteins, and Small Molecule Manu- Activities Research Research
Slide 29: Biotech Market Evolving Into Digital Ecosystem
Biotech Market Evolving Into Digital Ecosystem Molecular biology Drug discovery Synthetic biology High-Precision Tools & High-throughput Synthetic Genomes & Current market needs Automation Screening & Biomarkers Microbial Factories Automated systems for Technologies for rapid Regulatory-compliant In
Slide 30: Total and Serviceable Addressable Market
Total and Serviceable Addressable Market Global TAM (by market segment, 2023, USDbn) Global SAM (by 2023, USDbn) Potential market size, independently from BICO’s ability Market size based on customers BICO can serve with to reach and serve it existing business Total ~3bn, average CAGR: +12% In-vitro
Slide 31: Lab Automation Industry Evolving Significantly
Lab Automation Industry Evolving significantly • Market size valued around USD 5.5-6.8bn in 2023 • Growth rate indicated at CAGR 6.3-9.3% in 2023 to 2035 • Integrated automated solutions market we estimate to USD 1.1-1.3 bn and expected to continue to grow faster than the overall lab automation mark
Slide 32: Consumables Attractive Segment in the Market BICO Addresses
Consumables Attractive Segment in the Market BICO Addresses TAM: Product segments >15% Software ~25% 3% Hardware 10% 26% • ~45% 44% Consumables 12% 121bn 27% Services 11% 32 Source: BICO Annual Report; Riksbank; Market reports (Portfolio TAM project); EY-Parthenon analysis
Slide 33: Opportunity to Increase Share of Consumables, Service and Software
Opportunity to Increase Share of Consumables, Service and Software Revenue breakdown (2023, SEKm) Total SEK 2,250m Consumables, Service and Software Instruments 33 Source: Company information; EY-Parthenon analysis
Slide 34: Pharma and Biotech Attractive Segments Requiring Higher Regulatory Standards
Pharma and Biotech Attractive Segments Requiring Higher Regulatory Standards 30% 25% Biotechnology R&D spend, % of sales 20% Pharmaceuticals 15% Academia MedTech 10% Diagnostics Animal Health 5% Agricultural Biotechnology Cosmetic industry 1% Nutraceuticals 0% Low High Level of regulation 34 Source:
Slide 35: BICO to Address Needs Holistically Through End-to-End Workflows
BICO to Address Needs Holistically Through End-to-End Workflows Field Molecular biology Drug Discovery SynBio Share of revenue Hit Biologics, Basic Diagnostic Target Lead Animal Clinical proteins, Activity generation small Today Ambition research testing discovery optimization models trials & lead i
Slide 36: Key Trends for BICO
Key Trends for BICO – Growing demand – Technologies for rapid – Growing adoption of for integrated and compound screening in-vitro testing instead automated workflows and hit to lead of animal testing* in labs for higher generation – Regulatory compliant efficiency and – Increased focus on platforms
Slide 37: Vision and Mission
Vision BICO enables and automates the life science lab of the future Mission Be the first-choice lab automation partner and provider of selected workflows to pharma and biotech 37
Slide 38: Strategic Priorities
Strategic Priorities 1. 2. 3. 4. Complete Invest in Continue Drive Strategic People & Operational Commercial Review Culture Excellence Excellence Initiatives 38
Slide 39: Strategic Focus Areas: Drive Commercial Excellence
Strategic Focus Areas – Our Solution to the Customer Needs 1. Drive Commercial Excellence Further develop Ensure Provide Enable Increase integrated Regulatory Scientific End-to-End recurring data, AI and Compliance Workflow Lab automation revenue SW solutions Readiness Solutions 39
Slide 40: Strategic Focus Areas: Complete Strategic Review
Strategic Focus Areas 2. Complete Strategic Review Continually Gate stage assess the Customer process for strategic fit centric product across our R&D development portfolio of assets 40
Slide 41: Strategic Focus Areas: Invest in People & Culture
Strategic Focus Areas 3. Invest in People & Culture Foster culture Plan, attract, Harmonize, Deliver global and strong and retain engage and HR operational leadership talent reward excellence 41
Slide 42: Strategic Focus Areas: Continue Operational Excellence Improvements
Strategic Focus Areas 4. Continue Operational Excellence Improvements Continued Roll out of focus on Implementation Streamlining Establishing strategic inventory of Global and cost Global Sourcing CDMO reduction and QA & RA reduction in organization partnership facility organization logistics model
Slide 43: Lab Automation and Selected Workflows are the Cornerstones in BICO's Offering
Lab Automation and Selected Workflows are the Cornerstones in BICO’s Offering Instruments Consumables Bioprinting Lab Automation and selected workflows Services Data, AI and software 43
Slide 44: Strategic Focus Areas: Drive Commercial Excellence
Strategic Focus Areas – Our Solution to the Customer Needs Drive Commercial Excellence Further develop Ensure Provide Enable Increase integrated Regulatory Scientific End-to-End recurring data, AI and Compliance Workflow Lab automation revenue SW solutions Readiness Solutions 44
Slide 45: Holistic Workflows Approached Using Three Levels of Integration
Holistic Workflows Approached Using Three Levels of Integration Customized automation Off the shelf work cell Standardized operating procedure Examples from G-Prep BICO’s portfolio Biosero’s automated Cytena’s C.Station a standardized solutions and tested NGS workflow Long implementation Medium Shor
Slide 46: The Problem / The BICO Solution
The Problem Discovering new drugs and marketable scientific innovations • Takes years of time The BICO Solution • Cost millions to billions of dollars • May be heavily regulated Accelerating scientific research through automation 46
Slide 47: Laboratory Automation: The breadth of solutions
Laboratory Automation: INTEGRATED The breadth of solutions FULLY- AUTOMATED AUTOMATED SEMI- AUTOMATED MANUAL BICO company Biosero consults and builds solutions along the entire spectrum 47
Slide 48: Laboratory Automation: The breadth of solutions
Laboratory Automation: INTEGRATED The breadth of solutions FULLY- AUTOMATED AUTOMATED SEMI- AUTOMATED MANUAL Connecting equipment through Biosero's Green Button Go® Software 48
Slide 49: The Impact of Automation
The Impact of Automation Reduce downstream Increase existing Maximize productivity process and assay equipment capacity to of development scientists development by up develop biopharmaceutical and labs by a minimum to 75% manufacturing processes of 200% by 400% 49
Slide 50: New C.WASH PLUS: Multiple BICO Products Working Together
New C.WASH PLUS: Enabled by Green Button Go® Multiple BICO Products Working Together 50
Slide 51: BICO Leads the Way in Solving Challenges in Life Science
BICO Leads the Way in Solving the Challenges in Life Science with Speed, Accuracy, and Efficiency Speed • Reducing the time to find optimal candidates for treatment therapies Accuracy • Driving forward a personalized approach in treatment • Enabling the development of physiologically relevant models
Slide 52: BICO Vision and Strategic Agenda
BICO Vision and Strategic Agenda BICO ENABLES AND AUTOMATES Vision THE LIFE SCIENCE LAB OF THE FUTURE Mission Be the first-choice lab automation partner and provider of selected workflows to pharma and biotech Enable end-to-end Further develop Ensure regulatory Provide scientific Increase Strategic
Slide 53: 53
53
Slide 54: Break (15 minutes)
15 minutes break 54
Slide 55: New Business Areas and Comment on Financial Targets
New Business Areas and Comment on Financial Targets 55
Slide 56: New Business Areas
» ~ Z Sa eC . Ss SS 2S SS ¢ New Business Areas) 7 }) o L Y , “al s
Slide 57: Current Business Areas
Current Business Areas BIOPRINTING BIOSCIENCES BIOAUTOMATION 57
Slide 58: New Business Areas
New Business Areas LAB AUTOMATION LIFE SCIENCE SOLUTIONS BIOPRINTING 58
Slide 59: Be the First-choice Lab Automation Partner and Provider of Selected Workflows
Be the First-choice Lab Automation Partner and Provider of Selected Workflows to Pharma and Biotech LIFE SCIENCE LAB AUTOMATION BIOPRINTING SOLUTIONS 59
Slide 60: Serviceable Addressable Market by Business Area
Service Adressable Market by Business Area, USDm Total ~3bn, average CAGR: +12% LAB AUTOMATION LIFE SCIENCE BIOPRINTING ~ 1,100-1,300 SOLUTIONS ~300 USD million USD million ~ 1,400 USD million 60
Slide 61: Revenue per Business Area, FY 2023
Revenue per Business Area, FY 2023 OLD BUSINESS AREAS BIOSCIENCES BIOAUTOMATION BIOPRINTING SEK 1,107m SEK 482m SEK 661m NEW BUSINESS AREAS LIFE SCIENCE LAB AUTOMATION BIOPRINTING SOLUTIONS SEK 503m SEK 661m SEK 1,087m 61
Slide 62: Sales, Adjusted EBITDA and EBITDA Margin by Business Area
Sales, Adjusted EBITDA and EBITDA Margin by Business Area* OLD BUSINESS AREAS Biosciences Bioautomation Bioprinting SEKm FY 2022 FY 2023 H1 2024 FY 2022 FY 2023 H1 2024 FY 2022 FY 2023 H1 2024 Sales 956 1,107 593 533 482 183 632 661 268 Adjusted EBITDA 46 150 58 111 64 24 69 87 2 Adjusted EBITDA mar
Slide 63: Organization to Deliver on the Strategy
Organization to Deliver on the Strategy Group President CCO CFO COO GC CHRO and CEO Jacob EMT Anders Fogelberg Marius Andréas Catharina Maria Forss Thordenberg Balger Joersjö Nordlund Finance Operations Legal HR • Business • Operations • Corporate • Global Control & Organization Governance HR Dev •
Slide 64: Financial Targets
» ~ A Sa a Ss S35 2S Se Z Financial Targets = ~ }) vg Y , “al s
Slide 65: Current Financial Targets
Current Financial Targets • Introduced during the Capital Markets Day in November 2022 • Valid since 2023 on a mid-term basis (within three years) Double-digit EBITDA Margin organic growth in less capitalized Net Debt to constant currency development cost EBITDA <3.0x > 10% 65
Slide 66: Outcome: Financial Targets
Outcome: Financial Targets As reported in Annual Report 2023, Q1 2024 and Q2 2024 report. Excluding Ginolis Financial target FY 2023 Q1 2024 Q2 2024 Double-digit organic growth in constant 0.3% 4.7% -1.8% currency Adjusted EBITDA margin 5.1% 4.5%* 7.0%* less capitalized development cost > 10% Net De
Slide 67: BICO Reiterates Current Financial Targets
BICO Reiterates Current Financial Targets • Introduced during the Capital Markets Day in November 2022 • Reiterated during Capital Markets Day in September 2024 • Updated long-term Financial Targets to be defined after achievement of current targets Double-digit EBITDA Margin organic growth in less
Slide 68: Slide 68
Slide 69: Lab Automation with Biosero
Lab Automation with Biosero With Customer Spotlight on DeepCure 69
Slide 70: The Problem
The Problem Discovering drugs, cures, therapies, and diagnostics takes longer and costs more than it should. 70
Slide 71: Why Labs Automate and Why They Haven't
Why Labs Automate and Why They Haven’t! It starts by exploring a better way to do science Reproducibility Quality Productivity Efficiency Safety Sustainability 71
Slide 72: Trends in Lab Automation
Trends in Lab Automation LAB AUTOMATION IS NEEDED CLOSER TO THE PATIENT and in more regulated environments LABS ARE MORE OPEN TO BUYING A STRONG OFF-THE-SHELF SOLUTION THAN EVER BEFORE because of pressures in their own businesses THE DEMOGRAPHICS IN LAB AUTOMATION ARE EVOLVING into a more diverse fi
Slide 73: Laboratory Automation: The breadth of solutions
Laboratory Automation: INTEGRATED The breadth of solutions FULLY- AUTOMATED AUTOMATED SEMI- AUTOMATED MANUAL 73
Slide 74: What Does Lab Automation Entail?
What Does Lab Automation Entail? ROBOTICS, WORKFLOWS, & NO DATA LEFT BEHIND PHYSICAL LOGICAL DATA 74
Slide 75: How Laboratory Automation Comes to Life
How Laboratory Automation Comes to Life ORCHESTRATING THE FLOW OF SAMPLES AND DATA ACROSS THE LAB 75
Slide 76: Experiment Data and Sample Data
Foil Seal Applied at Particulates 134ºC Transfer DMSO Backfill 10 uL Dispense Tip Wash Media Exchange Detected Error EXPERIMENT DATA SAMPLE DATA SAMPLE VOLUME CONC. BARCODE LOT ID (uL) (mM) ARB348585 17378492 3046 800 10 DRE552671 37828910 56729 580 10 Incubator Temp Seal Removed Freeze/Thaw Centrif
Slide 77: Software-Centric Model Supported by Lab Automation Design and Engineering Services
Software-Centric Model Supported by Lab Automation Design and Engineering Services 77
Slide 78: Molecular Foundry
MOLECULAR FOUNDRY Revolutionizing R&D innovation by automating complex chemical synthesis © DeepCure, Inc. All Rights Reserved.
Slide 79: DeepCure is an AI leader in chemistry technologies for drug discovery
3 DeepCure is an AI leader in chemistry technologies for drug discovery DRUG DISCOVERY PROGRAMS 2024 SELECTED Therapeutics company Leader in AI World’s most advanced FIRST IND chemistry automation ENABLING COMPOUND IN INFLAMMATION 41 TEAM MEMBERS DeepCure with Generate Biomedicines, DeepCure with Re
Slide 80: Organic chemistry innovation is stifled by the inefficiency of manual synthesis
Organic chemistry innovation is stifled by the inefficiency of manual synthesis INDUSTRY STANDARDS IN DRUG DISCOVERY TODAY 1-2 compounds/FTE*/week ~$350k $90k+ yr/pharma FTE /yr/CRO FTE1 A century old process that is very slow & expensive 1.5-2 years for lead optimization2 Photo credit: USPTO. FTE r
Slide 81: Manual chemistry synthesis severely limits R&D innovation
PROBLEM Manual chemistry synthesis severely limits R&D innovation Manual processes are Inadequate slow & expensive chemical Low success Few compounds diversity rates being tested Circa 1900 What we would like to test 20-34%1,2 What we can practically Credit: Wellcome Library, London. test Chemists a
Slide 82: AI designs molecules that traditional chemistry struggles to support
A diverse chemical space is much more likely to Values are the % molecules that meet minimum requirements of have compounds that the TCP (target candidate profile) meet all requirements Commercial library DeepCure non-commercial chemical space logd = LogD at pH7.4, caco2 = CaCo2 permeability; mmc =
Slide 83: Build a fully automated chemistry platform leveraging Biosero's expertise
SOLUTION Build a fully automated chemistry platform from planning to synthesis leveraging Biosero’s expertise Impact: more time + money for researchers to find better, safer molecules Fully integrates software to internal AI systems © All © DeepCure, Rights Inc. Reserved All Rights Reserved.
Slide 84: Biosero Green Button Go Process Flow
Biosero Green Button Go Process Flow Synthesis Analytical Prep Weigh GBG GBG GBG 10 12 GBG GBG © DeepCure, Inc. All Rights Reserved.
Slide 85: Molecular Foundry makes real-time scientific decisions with Biosero software
Deepcure’s Molecular Foundry makes real-time scientific decisions due to Biosero’s software integrations + AI or human input Compounds selected Synthesis & reaction planning Multi-step synthesis Synthesize and purify Measure properties directed with GBG compounds Next iteration of compounds GBG GBG
Slide 86: Scientists can tackle the tough questions while the Molecular Foundry generates compounds
Scientists can tackle the tough questions while the Molecular Foundry generates new compounds BOTTLENECKS OPPORTUNITIES Manual chemistry data is difficult to build Big and standardized chemical synthesis models on data enables predictive models Timely and expensive R&D projects with Faster turnaroun
Slide 87: The foundry delivers a paradigm shift
The foundry delivers a paradigm shift The next generation of small molecule drug discovery: AI with fully integrated robotic labs FOUNDRY Custom synthesis 1 100 Foundry chemists 1-2 8 weeks weeks 150-300 discrete ~$500k-1M compounds, with 3- <$10k 10 purification steps * Estimates depends on many fa
Slide 88: 1st fully automated synthesis of a top selling drug and its close analogues
DEMONSTRATION STUDY 1st fully automated synthesis of a top selling drug and its close analogues Shows we can rapidly make complex molecules and diverse analogs Nirmatrelvir: 6 stereocenters & active ingredient in #4 selling drug (2022) Yield: 30 mg at 98% purity in 8 days (confirmed by NMR & LC-MS)
Slide 89: Automating Chemistry to Accelerate Innovation
TM Automating Chemistry to Accelerate Innovation
Slide 90: Solutions to Address the Industry's Greatest Needs
Solutions to Address the Industry’s Greatest Needs Support Increase Seamless Enable Cost Productivity Technology Reductions and Transfer across Throughput the Globe Safe and Sustainable Enable Rapid Enhance Solutions Reproducibility Quality (Monitor, Miniaturize, Minimize) 90
Slide 91: Biosero's Growth Strategy
Biosero’s Growth Strategy STRATEGIC LEVERS FOR GROWTH FOR THE NEXT FIVE YEARS END-TO-END ORCHESTRATION SCIENTIFIC, WORKFLOW-CENTRIC for Pharma, Biotech Plus AUTOMATED SOLUTIONS Agriscience and Diagnostics Cell Line Development, NGS, Extraction SOFTWARE-CENTRIC SOLUTIONS INCREASING RECURRING for Inst
Slide 92: Accelerating Research and Discovery
Accelerating Research and Discovery GREEN BUTTON GO INTEGRATION SOFTWARE & BIOSERO AUTOMATION SOLUTIONS 92
Slide 93: Vision and Mission
Vision BICO enables and automates the life science lab of the future Mission Be the first-choice lab automation partner and provider of selected workflows to pharma and biotech 93
Slide 94: 94
94
Slide 95: Break (15 minutes)
15 minutes break
Slide 96: Q&A with BICO's Executive Management
Q&A with BICO’S Executive Management
Slide 97: Participating in the Q&A session
Participating in the Q&A session Ulrik Trattner Maria Forss Jacob Thordenberg Ryan Bernhardt Moderator President & CEO CFO BICO CEO Biosero Equity Analyst, BICO Carnegie 97
Slide 98: 98
98
Slide 99: Thank you!
Thank you! RECORDINGS AVAILABLE ON BICO.COM OR VIA THE QR-CODE 99 2024-09-17
Slide 100: 2024-09-17
100 2024-09-17